China Rewrites Its Drug Pricing Rules for the First Time in Eleven Years
China State Council Office Notice [2026] No. 9 signals a structural shift in how China values innovation. What it says and what needs to happen before any of it applies to medical devices.
On 14 April 2026, the China State Council Office Notice Guobanfa [2026] No. 9 ( 国办发[2026] 9号 ), Opinions on Improving the Drug Price Formation Mechanism. It is the first national framework document on drug pricing issued under the authority of the State Council Office since 2015, when China abolished government-set drug prices. At a policy briefing the following day, NHSA Director of Drug Pricing and Procurement, Wang Xiaoning, stated that volume-based procurement “does not cover innovative drugs.” That statement, combined with the document’s text, has been widely read as a turning point for innovation pricing. The reading is directionally correct but operationally premature, and for companies in the device and consumable sector, the distance between the signal and an executable rule is significant.
What the Document Actually Says
Three mechanisms are established or formalised by the document:
A first-launch pricing mechanism for new drugs. Newly listed drugs will operate under an enterprise self-assessment system, with companies setting prices based on clinical value, market conditions, competitive landscape, and social affordability. For high-level innovative drugs with high clinical value, the document supports pricing commensurate with high investment and high risk at the time of launch, with relative price stability maintained “for a defined period.” The duration of that period is not specified in the document and was not defined at the press briefing. It is an intentionally open parameter, subject to forthcoming implementation guidelines.
A commercial insurance pathway for innovative drugs. The document formally incorporates commercial health insurance as a payment channel for innovative drugs, and references the accelerated implementation of the Commercial Health Insurance Innovative Drug List. The first edition of that list, covering 19 drugs including CAR-T therapies and an Alzheimer’s treatment, took effect on 1 January 2026. Products on the list carry three administrative exemptions: they are excluded from hospital self-pay ratio assessments, excluded from VBP-substitute monitoring, and excluded from DRG/DIP episode payment calculations.
A normalised VBP framework targeting mature, multi-supplier drugs. The document defines the scope of volume-based procurement as drugs that are “multi-sourced and long-established.” This is the basis for Wang Xiaoning’s statement that VBP does not cover innovative drugs. It is a clarification of scope, not a new exemption. VBP was designed for commoditised products and was never intended for first-launch innovations. What is new is the explicit national codification of this boundary.
From the original text: “For high-level innovative drugs with high innovation and high clinical value, [the State Council] supports pricing commensurate with high investment and high risk at the time of market launch, and maintaining relatively stable prices for a defined period.”
(Original: “对创新程度高、临床价值大的高水平创新药，支持在上市初期制定与高投入、高风险相符的价格，在一定时期内保持价格相对稳定。”)
The Two Execution Gaps That Matter
Gap one: the innovation recognition standard does not yet exist. The document supports pricing protection for drugs with “high level of innovation” and “high clinical value”, but the criteria for making that determination are described as “under development.” No operational definition has been published. No self-assessment template is available. Until these criteria are established and the first-launch price mechanism is implemented, companies cannot use this framework to defend a price. The signal is real; the instrument is not yet ready.
Gap two: the device sector requires its own document. The policy-execution gap is most significant for companies in the medical device and consumable sector. Document [2026] No. 9 has explicit legal force over drugs. Its application to medical devices requires independent action by NMPA and NHSA, separate regulatory instruments that have not been initiated as of the document’s publication. Companies in ophthalmics, orthopaedics, cardiovascular devices, or any other high-value consumable category cannot cite No. 9 as the basis for a pricing or procurement argument. The logic may transmit; the rule has not.
Commercial Insurance: A Third Channel, With Limits
The commercial insurance mechanism deserves attention separately from the VBP question, because it is already operational rather than pending.
The first Commercial Health Insurance Innovative Drug List is live. As of 1 January 2026, the list covers 19 drugs. Several cities have moved quickly: Shenzhen’s Huimin Bao product has incorporated all 19 drugs into its 2025 coverage; Shantou’s version raises the reimbursement ratio by ten percentage points for hospitalisation involving listed products. In 2024, city-level supplemental insurance and million-yuan medical insurance products combined paid approximately RMB 4.5 billion in innovative drug costs, a growing but still narrow figure relative to basic insurance’s RMB 460 billion expenditure on negotiated drugs.
Device coverage exists in parallel. Several Chinese commercial health insurance products already cover high-value medical consumables outside the basic insurance scope. Jiangsu’s 2026 Medical Huibao covers medical-insurance-excluded high-value consumables. Guangzhou’s Suixinbao covers innovative drugs and devices approved under the Greater Bay Area drug and device access scheme. Shanghai’s Lingang Blue Bay Plan covers new consumables not yet in the standard insurance catalogue. These products operate outside the national Innovative Drug List framework but serve the same structural function: bridging the gap between basic insurance coverage and clinical reality.
The structural limit. The Commercial Innovative Drug List is a reference document, not a mandate. Insurance companies incorporate listed products voluntarily. Coverage penetration varies significantly across cities and products. For device companies, no equivalent national list currently exists; the device-side commercial insurance coverage is city-specific and product-specific, without a central framework to accelerate adoption.
What This Means for Multinational Healthcare Companies
Companies such as Alcon, Zeiss, Johnson & Johnson, Novartis, and Roche operate across drugs, devices, and consumables simultaneously. Document [2026] No. 9 affects these portfolios asymmetrically.
For the drug portfolio: the strategic window is opening. A multinational company launching an innovative drug in China for the first time now has a national framework that explicitly supports early-launch pricing commensurate with R&D investment. This changes the global launch sequencing calculation, China has historically been excluded from or deprioritised in global launch waves because of its price-suppression environment. Document [2026] No. 9 is the first formal signal that this environment is changing. The practical tools are not yet available, but the policy direction is set at the State Council level.
For the device and consumable portfolio: the current path is unchanged. Innovation in medical devices is recognised and encouraged at the regulatory level through NMPA’s Special Review Pathway for Innovative Medical Devices. But that recognition does not currently confer pricing protection or VBP exemption. Device companies that want to position a product as innovation-protected need to watch for a separate NMPA/NHSA instrument that would mirror the No. 9 logic on the device side. Until that instrument exists, the pathway remains: regulatory approval, market listing, procurement platform registration, and, for high-volume standardised products, eventual VBP inclusion.
For the ophthalmic portfolio specifically: premium intraocular lenses occupy an instructive position. Trifocal and EDOF IOLs were included in the fourth national VBP round for high-value consumables in 2023, which means they have already been treated as multi-supplier, market-mature products rather than protected innovations. Reversing that classification for existing products would require a separate policy intervention. What Document [2026] No. 9 creates, however, is a policy framework that a genuinely novel ophthalmic device, one meeting NMPA’s innovation criteria and not yet subject to VBP, could eventually benefit from, if and when device-side rules are established. The window is not open yet, but the policy architecture that would open it is now visible.
Key Implications
State Council Office Notice Document [2026] No. 9 is the most significant national drug pricing document since China’s 2015 price liberalisation, and it establishes an unambiguous policy direction: high-value innovation warrants protected pricing at launch. For pharmaceutical portfolios, the strategic implication is immediate; China’s historical role as a late or low-priority launch market requires reassessment. For device and consumable portfolios, the policy-execution gap is substantial: the document’s logic does not transfer automatically, and the separate regulatory instruments needed to make it operational on the device side have not yet been drafted. Companies with mixed drug-device portfolios should evaluate their China innovation pipeline through both lenses simultaneously, and monitor NMPA and NHSA for device-side implementation signals that would operationalise the No. 9 framework for high-value consumables.
This content is for informational purposes only and does not constitute legal, regulatory, investment, or medical advice. China’s healthcare policy environment moves quickly; the status of any regulatory development should be verified independently before informing a commercial or compliance decision. OphthalLogix Intelligence accepts no liability for decisions made in reliance on this content.
— The OphthalLogix Intelligence Team
